Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy
Sannova Analytical’s Post
More Relevant Posts
-
Discover how decentralized manufacturing is reshaping the landscape of cell and gene therapy development in this blog capturing insights from our Bridging the Gap webinar series. Gain valuable insights from experts like Dorothea Ledergerber, PhD, Chief Technical Officer at Tigen Pharma, and Patrick Hanley, PhD, Director of the Cellular Therapy Program at Children’s National Hospital. Read the full blog and register for future webinars here: https://hubs.ly/Q02xHWy70 #CellTherapy #GeneTherapy #Innovation #WebinarSeries
-
-
Come join Senthil Ramaswamy and I as we discuss the critical needs for the future of Cell and Gene Therapies
Join us on June 13 for an insightful webinar on the revolutionary innovations that are shaping the cell and gene therapy manufacturing space. In this webinar, we will explore the complex landscape of process development and analytical development, while reviewing key focus areas based on lessons learned across our experiences. The discussion will be framed around where the market is headed and how breakthroughs will make for a bright future. Register today on https://lnkd.in/gKutKXGY Date: Thursday, June 13, 2024 Time: 11am EDT | 5pm CET Speaker: Mark Santos, Global Head of Commercial Development and Strategic Marketing, Cell & Gene Technologies #celltherapy #genetherapy #LonzaCGT #RealizingPotentialTogether
-
-
Advancement in critical therapeutic niches is one of the factors behind the domination of specialty-based drugs in the pharma industry. CRISPR therapy, RNA-based research, and cell and gene therapy research are some of the technologies being leveraged in the specialty-based arena. What are the implications of the specialty landscape? How are primary care physicians getting familiarized with specialty-based drugs? Christina Fresta, MPH, Strategic Solutions Senior Manager at epocrates, talks about this and more here: https://bit.ly/48P3nk4 #epocrates #healthcareIT #technologyandinnovation #specialtydrugs
-
-
📢 Don't miss tomorrow's Cell & Gene Therapy Insights’ webinar on unlocking success in CAR T tech transfer, featuring expert panelists, Sara Mills at Dark Horse Consulting Group Inc., Neil Blackburn at OmniaBio, and Dan Miskimin at BrainChild Bio. Register today: https://lnkd.in/gJbqp7T9 Key topics: ➡️ Discuss typical obstacles encountered in tech transfer and how to proactively address them. ➡️ Discover how to master the CAR T cell therapy tech transfer process. ➡️ Learn from a real-world case study showing how to achieve seamless transition to GMP manufacturing. #CellandGeneTherapy #CellTherapy #GeneTherapy #Webinar
-
-
A virus wrangler, turning villains to heroes | Gene Therapy | Research and Development | Protein Engineering and Production | Project Leadership and Management
FDA has released a draft guidance titled “Platform Technology Designation Program for Drug Development” (https://lnkd.in/dSyWGUY4), aimed at accelerating future drug applications for subsequent treatments derived from the same platform technology. A platform technology is defined as a well-understood and reproducible technology, which may include a nucleic acid sequence, molecular structure, mechanism of action, delivery method, vector, or a combination of these technologies. This can ease gene therapy regulatory burden and speed up next generation therapies. #FDA #GeneTherapy #Regulation #Guidance https://lnkd.in/d57D_r73
-
-
In an industry where change is ever constant, Andelyn Biosciences stands as your steadfast partner in gene therapy manufacturing. With over two decades of experience and expertise, our commitment to growth and innovation ensures we're here for you, ready to bring your groundbreaking therapies from the lab to the patient. See what a feasibility study and yield assessment can do to get your program started on a path to process industrialization: https://buff.ly/3UzqzNP #andelynbiosciences
-
-
Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C>) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C> field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24
-
-
How do you choose the right CDMO for gene engineering? David Hermanson, Director of Cell and Gene Therapy Applications at Bio-Techne, participated in a dynamic panel, hosted by ISCT, to discuss this topic. Together with industry experts Jeff Liter, Luminary Therapeutics and Farzin Farzeneh, Virocell, they explored the critical factors to consider when sourcing a CDMO. Discover key insights from their conversation in our latest blog post, where we also explore the use of viral and non-viral methods. Read more now: bit.ly/4cYQuX8
-
-
Interesting article regarding the future of cell and gene therapies and the cold chain logistics they require. Our VP of Cell and Gene Therapies Emilio Frattaruolo, CPPL is always happy to discuss your specific requirements!
How are current innovations shaping the future of cell and gene therapies and cold chain logistics? "This interview explores the increasing demand for real-time visibility technologies and high-performance shipping solutions. Emilio Frattaruolo, CPPL, VP of Cell and Gene Therapies, highlights the importance of thinking holistically about supply chains, from early-stage research through to commercialization and scaling up for larger patient populations." Watch it now! ➡️ https://hubs.li/Q02HP7Fl0 #CellAndGeneTherapies #ColdChainLogistics #PharmaSupplyChain Fierce Biotech
-
-
#Webinar now available on demand! Improving #viralvector titer and impurity analyses with automated #ELISAsystems Daniel Forsström (R&D Application and Custom Service Manager, Gyros Protein Technologies) explores how automating the manual ELISA process streamlines cell and #genetherapy workflows, increases accuracy, and saves valuable time and resources. Watch this webinar to: • Learn how the use of open platforms can increase productivity in gene therapy development • Discover approaches to accelerate plate-based ELISA assays • Investigate reagent-efficient assay alternatives for impurity data generation Watch at your convenience below:
